請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68169
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳惠文(Huei-Wen Chen) | |
dc.contributor.author | Chia-Ter Chao | en |
dc.contributor.author | 趙家德 | zh_TW |
dc.date.accessioned | 2021-06-17T02:13:56Z | - |
dc.date.available | 2019-11-30 | |
dc.date.copyright | 2018-03-29 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-11-22 | |
dc.identifier.citation | 1. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med. 1998;339(12):799-805. 2. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LM, Ansell D, Collart F, Finne P, Heaf JG, De Meester J, Wetzels JF, Rosendaal FR, Dekker FW. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782-1789. 3. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16-S23. 4. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease. Hypertension. 2003;42(5):1050-1065. 5. Mizobuchi M, Towler D, Slatopolsky E. Vascular Calcification: The Killer of Patients with Chronic Kidney Disease. J Am Soc Nephrol. 2009;20(7):1453-1464. 6. Lehto S , Niskanen L, Suhonen M, Ronnemaa T, Laakso M. Medial artery calcification: a neglected harbinger of cardiovascular complications in non-insulin dependent diabetes mellitus. Arterioscler Thromb Vasc Biol. 1996;16(8):978-1093. 7. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial medial calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18(9):1731-1740. 8. Lanzer P, Boehm M, Sorribas V, Thiriet M, Janzen J, Zeller T, St Hilaire C, Shanahan C. Medial vascular calcification revisited: review and perspectives. Eur Heart J. 2014;35(23):1515-1525. 9. Jean G, Mayor B, Deleaval P, Lorriaux C, Hurot JM, Bresson E, Chazot C. Vascular Calcification Progression Is an Independent Predictor of Mortality in Patients on Haemodialysis. Nephron. 2015;130(3):169-174. 10. Lee MJ, Shin DH, Kim SJ, Oh HJ, Yoo DE, Ko KI, Koo HM, Kim CH, Doh FM, Park JT, Han SH, Yoo TH, Choi KH, Kang SW. Progression of Aortic Arch Calcification Over 1 Year Is an Independent Predictor of Mortality in Incident Peritoneal Dialysis Patients. PLoS ONE. 2012;7(11):e48793. 11. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91(4):1800-1809. 12. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol. 2010;7(9):528-536. 13. Collett GD, Canfield AE. Angiogenesis and pericytes in the initiation of ectopic calcification. Circ Res. 2005;96(9):930-938. 14. Wirrig EE, Yutzey KE. Conserved transcriptional regulatory mechanisms in aortic valve development and disease. Arterioscler Thromb Vasc Biol. 2014;34(4):737-741. 15. Cheng SL, Behrmann A, Shao JS, Ramachandran B, Krchma K, Bello Arredondo Y, Kovacs A, Mead M, Maxson R, Towler DA. Targeted reduction of vascular Msx1 and Msx2 mitigates arteriosclerotic calcification and aortic stiffness in LDLR-deficient mice fed diabetogenic diets. Diabetes. 2014;63(12):4326-4337. 16. Vasuri F, Fittipaldi S, Pasquinelli G. Arterial calcification: finger-pointing at resident and circulating stem cells. World J Stem Cells. 2014;6(5):540-551. 17. Speer MY, Yang HY, Brabb T, Leaf E, Look A, Lin WL, Frutkin A, Dichek D, Giachelli CM. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res. 2009;104(6):733-741. 18. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. 2011;469(7330):336-342. 19. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher AM, Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324(5935):1710-1713. 20. Rangrez AY, M’Baya-Moutoula E, Metzinger-Le Meuth V, Henaut L, Djelouat MS, Benchitrit J, Massy ZA, Metzinger L. Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. PLoS One. 2012;7(10):e47807. 21. Goettsch C, Rauner M, Pacyna N, Hempel U, Bornstein SR, Hofbauer LC. miR-125b Regulates Calcification of Vascular Smooth Muscle Cells. Am J Pathol. 2011;179(4):1594-1600. 22. Liao X-B, Zhang Z-Y, Yuan K, Liu Y, Feng X, Cui R-R, Hu YR, Yuan ZS, Gu L, Li SJ, Mao DA, Lu Q, Zhou XM, de Jesus Perez VA, Yuan LQ. MiR-133a Modulates Osteogenic Differentiation of Vascular Smooth Muscle Cells. Endocrinology. 2013;154(9):3344-3352. 23. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. miR-143 and miR-145: Molecular Keys to Switch the Phenotype of Vascular Smooth Muscle Cells. Circ Cardiovasc Genet. 2011;4(2):197-205. 24. Massy ZA, Drueke TB. Vascular calficiation. Curr Opin Nephrol Hypertens. 2013;22(4):405-412. 25. Massy ZA, Metzinger-Le Meuth V, Metzinger L. MicroRNAs are associated with uremic toxicity, cardiovascular calcification, and disease. Contrib Nephrol. 2017;189:160-168. 26. Mackenzie NC, Staines KA, Zhu D, Genever P, Macrae VE. miRNA-221 and miRNA-222 synergistically function to promote vascular calcification. Cell Biochem Funct. 2014;32(2):209-216. 27. Gui T, Zhou G, Sun Y, Shimokado A, Itoh S, Oikawa K, Muragaki Y. MicroRNAs that target Ca2+ transporters are involved in vascular smooth muscle cell calcification. Lab Invest. 2012;92(9):1250-1259. 28. Jansen F, Yang X, Proebsting S, Hoelscher M, Przybilla D, Baumann K, Schmitz T, Dolf A, Endl E, Franklin BS, Sinning JM, Vasa-Nicotera M, Nickenig G, Werner N. MicroRNA Expression in Circulating Microvesicles Predicts Cardiovascular Events in Patients With Coronary Artery Disease. J Am Heart Assoc. 2014;3(6):e001249. 29. Huang S, Chen M, Li L, He Ma, Hu D, Zhang X, Li J, Tanguay RM, Feng J, Cheng L, Zeng H, Dai X, Deng Q, Hu FB, Wu T. Circulating MicroRNAs and the Occurrence of Acute Myocardial Infarction in Chinese Populations. Circ Cardiovasc Genet. 2014;7(2):189-198. 30. Jin H, Li C, Ge H, Jiang Y, Li Y. Circulating microRNA: a novel potential biomarker for early diagnosis of Intracranial Aneurysm Rupture: a case control study. J Transl Med. 2013;11:296. 31. Ciceri P, Volpi E, Brenna I, Arnaboldi L, Neri L, Brancaccio D, Cozzolino M. Combined effects of ascorbic acid and phosphate on rat VSMC osteoblastic differentiation. Nephrol Dial Transplant. 2012;27(1):122-127. 32. Schwarzenbach H, da Silva AM, Calin G, Pantel K. Data normalization strategies for microRNA quantification. Clin Chem. 2015;61(11):1333-1342. 33. Marlet E, Atassi F, Motiani RK, Mougenot N, Jacquet A, Nadaud S, Capiod T, Trebak M, Lompre AM, Marchand A. miR-424/322 regulates vascular smooth muscle cell phenotype and neointimal formation in the rat. Cardiovasc Res. 2013;98(3):458-468. 34. Chen NX, Kiattisunthorn K, O’Neill KD, Chen X, Moorthi RN, Gattone VH 2nd, Allen MR, Moe SM. Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PLoS One. 2013;8(5):e64558. 35. Yang Z, Zheng B, Zhang Y, He M, Zhang XH, Ma D, Zhang RN, Wu XL, Wen JK. miR-155-dependent regulation of mammalian sterile 20-like kinase 2 (MST2) coordinates inflammation, oxidative stress and proliferation in vascular smooth muscle cells. Biochim Biophys Acta. 2015;1852(7):1477-1489. 36. Zheng B, Bernier M, Zhang XH, Suzuki T, Nie CQ, Li YH, Zhang Y, Song LL, Shi HJ, Liu Y, Zheng CY, Wen JK. miR-200c-SUMOylated KLF4 feedback loop acts as a switch in transcriptional programs that control VSMC proliferation. J Mol Cell Cardiol. 2015;82:201-212. 37. Chaturvedi P, Chen NX, O’Neill K, McClintick JN, Moe SM, Janga SC. Differential miRNA expression in cells and matrix vesicles in vascular smooth muscle cells from rats with kidney disease. PLoS One. 2015;10(6):e0131589. 38. Qian DH, Gao P, Feng H, Qin ZX, Li JB, Huang L. Down-regulation of mir-542-3p promotes neointimal formation in the aging rat. Vascul Pharmacol. 2015;72:118-129. 39. Hu W, Wang M, Yin H, Yao C, He Q, Yin L, Zhang C, Li W, Chang G, Wang S. MicroRNA-1298 is regulated by DNA methylation and affects vascular smooth muscle cell function by targeting connexin 43. Cardiovasc Res. 2015;107(4):534-545. 40. Sudo R, Sato F, Azechi T, Wachi H. MiR-29-mediated elastin down-regulation contributes to inorganic phosphorus-induced osteoblastic differentiation in vascular smooth muscle cells. Genes Cells. 2015;20(12):1077-1087. 41. Wang XW, He XJ, Lee KC, Huang C, Hu JB, Zhou R, Xiang XY, Feng B, Lu ZQ. MicroRNA-221 sponge therapy attenuates neointimal hyperplasia and improves blood flows in vein grafts. Int J Cardiol. 2016;208:79-86. 42. Panizo S, Naves-Diaz M, Carrillo-Lopez N, Martinez-Arias L, Fernandez-Martin JL, Ruiz-Torres MP, Cannata-Andia JB, Rodriguez I. MicroRNAs 29b, 133b, and 211 regulate vascular smooth muscle calcification mediated by high phosphorus. J Am Soc Nephrol. 2016;27(3):824-834. 43. Zahedi F, Nazari-Jahantigh M, Zhou Z, Subramanian P, Wei Y, Grommes J, Offermanns S, Steffens S, Weber C, Schober A. Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair. Cell Mol Life Sci. 2017;74(2):359-372. 44. Yang J, Chen L, Ding J, Fan Z, Li S, Wu H, Zhang J, Yang C, Wang H, Zeng P, Yang J. MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1. Gene. 2016;586(2):268-273. 45. Reddy MA, Das S, Zhuo C, Jin W, Wang M, Lanting L, Natarajan R. Regulation of vascular smooth muscle cell dysfunction under diabetic conditions by miR-504. Arterioscler Thromb Vasc Biol. 2016;36(5):864-873. 46. Zhang WF, Xiong YW, Zhu TT, Xiong AZ, Bao HH, Cheng XS. MicroRNA let-7g inhibited hypoxia-induced proliferation of PASMCs via G0/G1 cell cycle arrest by targeting c-myc. Life Sci. 2017;170:9-15. 47. Yang J, Fan Z, Yang J, Ding J, Yang C, Chen L. MicroRNA-24 attenuates neointimal hyperplasia in the diabetic rat carotid artery injury model by inhibiting Wnt4 signaling pathway. Int J Mol Sci. 2016;17(6):E765. 48. Wu J, Wang J, Li X, Liu X, Yu X, Tian Y. MicroRNA-145 mediates the formation of angiotensin II-induced murine abdominal aortic aneurysm. Heart Lung Circ. 2017;26(6):619-626. 49. Afzal TA, Luong LA, Chen D, Zhang C, Yang F, Chen Q, An W, Wilkes E, Yashiro K, Cutillas PR, Zhang L, Xiao Q. NCK associated protein 1 modulated by miRNA-214 determines vascular smooth muscle cell migration, proliferation, and neointimal hyperplasia. J Am Heart Assoc. 2016;5(12):e004629. 50. Li K, Wang Y, Zhang A, Liu B, Jia L. miR-379 inhibits cell proliferation, invasion, and migration of vascular smooth muscle cells by targeting insulin-like factor-1. Yonsei Med J. 2017;58(1):234-240. 51. Akiyoshi T, Ota H, Iijima K, Son BK, Kahyo T, Setou M, Ogawa S, Ouchi Y, Akishita M. A novel organ culture model of aorta for vascular calcification. Atherosclerosis. 2016;244:51-58. 52. Chao CT, Lee SY, Yang WS, Yen CJ, Chiang CK, Huang JW, Hung KY. Serum vitamin D levels are positively associated with varicella zoster immunity in chronic dialysis patients. Sci Rep. 2014;4:7371. 53. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella Rl, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-10518. 54. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods. 2010;50(4):298-301. 55. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12):5003-5008. 56. Yamada A, Cox MA, Gaffney KA, Moreland A, Boland CR, Goel A. Technical factors involved in the measurement of circulating microRNA biomarkers for the detection of colorectal neoplasia. PLoS One. 2014;9(11):e112481. 57. Hashimoto H, Iijima K, Hashimoto M, Son BK, Ota H, Ogawa S, Eto M, Akishita M, Ouchi Y. Validity and Usefulness of Aortic Arch Calcification in Chest X-Ray. J Atheroscler Thromb. 2009;16(3):256-264. 58. Li J, Galvin HK, Johnson SC, Lanston CS, Sclamberg J, Preston CA. Aortic calcification on plain chest radiography increases risk for coronary artery disease. Chest. 2002;121(5):1468-1471. 59. Iijima K, Ito Y, Son B-K, Akishita M, Ouchi Y. Pravastatin and Olmesartan Synergistically Ameliorate Renal Failure-Induced Vascular Calcification. J Atheroscler Thromb. 2014;21(9):917-929. 60. de Oca AM, Madueño JA, Martinez-Moreno JM, Guerrero F, Muñoz-Castañeda J, Rodriguez-Ortiz ME, Mendoza FJ, Almaden Y, Lopez I, Rodriguez M, Aguilera-Tejero E. High-phosphate-induced calcification is related to SM22α promoter methylation in vascular smooth muscle cells. J Bone Miner Res. 2010;25(9):1996-2005. 61. Yanagawa B, Lovren F, Pan Y, Garg V, Quan A, Tang G, Singh KK, Shukla PC, Kalra NP, Peterson MD, Verma S. miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. J Thorac Cardiovasc Surg. 2012;144(1):256-262. 62. Ohukainen P, Syvaranta S, Napankangas J, Rajamaki K, Taskinen P, Peltonen T, Helske-Suihko S, Kovanen PT, Ruskoaho H, Rysa J. MicroRNA-125b and chemokine CCL4 expression are associated with calcific aortic valve disease. Ann Med. 2015;47(5):423-429. 63. Kapustin AN, Chatrou ML, Drozdov I, Zheng Y, Davidson SM, Soong D, Furmanik M, Sanchis P, De Rosales RT, Alvarez-Hernandez D, Shriff R, Yin X, Muller K, Skepper JN, Mayr M, Reutelingsperger CP, Chester A, Bertazzo S, Schurgers LJ, Shanahan CM. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ Res. 2015;116(8):1312-1323. 64. Schousboe JT, Wilson KE, Hangartner TN. Detection of aortic calcification during vertebral fracture assessment (VFA) compared to digital radiography. PLoS One. 2007;2(8):e715. 65. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PWF. New induces to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997;132(2):245-250. 66. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum Phosphorus Levels Associate with Coronary Atherosclerosis in Young Adults. J Am Soc Nephrol. 2009;20(2):397-404. 67. Razzaque MS. Phosphate and vitamin D in chronic kidney disease. Contrib Nephrol. 2013;180:74-85. 68. Wolisi GO, Moe SM. Vitamin D in health and disease: the Role of Vitamin D in Vascular Calcification in Chronic Kidney Disease. Semin Dial. 2005;18(4):307-314. 69. Shang D, Xie Q, Ge X, Yan H, Tian J, Kuang D, Hao CM, Zhu T. Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients. BMC Nephrol. 2015;16:107. 70. Kraśniak A, Drożdż M, Pasowicz M, Chmiel G, Michałek M, Szumilak D, Podolec P, Klimeczek P, Konieczynska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007;22(2):515-521. 71. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing Dialysis. N Engl J Med. 2000;342(20):1478-1483. 72. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4):1327-1339. 73. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132(1):27-39. 74. Nam HS, Lee SM, Jeong EG, Lee DY, Son YK, Kim SE, Chung SH, Cho YR, Park JS, Lee SW, Noh MH, An WS. Vascular Calcification on Plain Radiographs Is Related with the Severity of Lesions Detected by Coronary Angiography in Dialysis Patients. Tohoku J Exp Med. 2015;235(2):135-144. 75. Bannas P, Jung C, Blanke P, Treszl A, Derlin T, Adam G, Bley TA. Severe aortic arch calcification depicted on chest radiography strongly suggests coronary artery calcification. Eur Radiol. 2013;23(10):2652-2657. 76. Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A, Lindholm B, Soderberg M, Wennberg L, Nordfors L, Ripsweden J, Barany P, Stenvinkel P. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 2015;88(6):1356-1364. 77. Brandenburg V, Kramann R, Koos R, Kruger T, Schurgers L, Muhlenbruch G, Hubner S, Gladziwa U, Drechsler C, Ketteler M. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol. 2013;14:219. 78. Liabeuf S, Okazaki H, Desjardins L, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Suleymanlar G, Mallamaci F, Zoccali C, London G, Massy ZA. Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario? Nephrol Dial Transplant. 2014;29(7):1275-1284. 79. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109(6):697-711. 80. Mizuno Y, Yagi K, Tokuzawa Y, Kanesaki-Yatsuka Y, Suda T, Katagiri T, Fukuda T, Maruyama M, Okuda A, Amemiya T, Kondoh Y, Tashiro H, Olazawa Y. miR-125b inhibits osteoblastic differentiation by down-regulation of cell proliferation. Biochem Biophys Res Commun. 2008;368(2):267-272. 81. Wen P, Cao H, Fang L, Ye H, Zhou Y, Jiang L, Su W, Xu H, He W, Dai C, Yang J. miR-125b/Ets1 axis regulates transdifferentiation and calcification of vascular smooth muscle cells in a high-phosphate environment. Exp Cell Res. 2014;322(2):302-312. 82. Huang K, Fu J, Zhou W, Li W, Dong S, Yu S, Hu Z, Wang H, Xie Z. MicroRNA-125b regulates osteogenic differentiation of mesenchymal stem cells by targeting Cbfβ in vitro. Biochimie. 2014;102:47-55. 83. Chen XL, Kiattisunthorn K, O’Neill KD, Chen X, MoorthI RN, Gattone II VH, Allen MR, Moe SM. Decreased microRNA is involved in the vascular remodeling abnormalities in chronic kidney disease (CKD). PLoS One. 2013;8(5):e64558. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68169 | - |
dc.description.abstract | 在末期腎病(end-stage renal disease)接受慢性透析的患者之中,血管鈣化(vascular calcification)以及其所帶來的血管彈性改變及血壓變化、是一種極為重要的死亡原因;然而、現有的各種檢驗以及檢查工具尚未能有效預測血管鈣化的進展以及惡化,因此發展出能夠預測此現象隨時間而改變狀態的生物標記(biomarker),是目前研究上亟待聚焦的課題.在本研究中,吾人假設循環中的分子、特別是胞外的微小核糖核酸(microRNA)有可能是潛在重要的有用標記,因此吾人利用三種不同的模型、分別是體外細胞模型、體外組織培養模型、以及動物模型來篩選出可能的微小核糖核酸標記,最後在末期腎病病人血清中進行檢驗其應用可行性.吾人將動物及人類的血管平滑肌細胞暴露於高磷培養基之中,接著利用Affymetrix的microRNA微陣列平台進行篩選、找出兩個microRNA標的在鈣化過程中會發生顯著改變,同時在培養基中驗證了只有一個microRNA標的會有同樣趨勢的改變;後續吾人在血管鈣化的動物模型以及體外主動脈培養的模型中觀察、此microRNA (miR-125b)在動物的主動脈以及血清中隨著血管鈣化的進展,是否有與體外模型之中類似的改變.前者結果發現,在動物主動脈以及血清中、miR-125b呈現出隨時間延續的表現量顯著下降,後者結果也發現,暴露於高磷狀態下的動物主動脈、組織miR-125b表現量也有顯著的下降,顯示在動物模型中、miR-125b有機會可以成為腎衰竭相關血管鈣化的進展指標.最後、吾人在末期腎病病人的血清中測試、循環中的miR-125b濃度是否與病人的血管鈣化相關.在一群共88位末期腎病病人的血清之中,吾人發現血清miR-125b表現量高低、與主動脈的鈣化嚴重度有獨立於年齡、及礦物質骨病變分子表現量以外的顯著關聯.此外、收案時的血清miR-125b表現量更被發現可以預測數年後的血管鈣化進展;這些發現顯示血清miR-125b表現量的確可以作為血管鈣化進展的預測因子. | zh_TW |
dc.description.abstract | Among end-stage renal disease patients receiving chronic dialysis, vascular calcification with its associated changes in vascular compliance and blood pressure is an extremely important contributor to mortality. However, existing assays and measurement approaches fail to predict the temporal progression of vascular calcification, particularly those related to chronic kidney disease. Thus the quest for and the validation of biomarkers capable of tracing the course of vascular calcification are the centerpiece in contemporary researches and remain unexplored. In this study, we hypothesized that circulating molecules, especially extracellular microRNAs, can be potentially important markers for uremic vascular calcification. We used different types of experimental models to simulate this pathologic process, including in vitro cell culture with calcification medium, ex vivo organ culture, and in vivo chronic kidney disease animal model to screen for candidate microRNAs, followed by validation in sera from patients with end-stage renal disease. We exposed rat and human vascular smooth muscle cells to high phosphate-containing medium, and extracted RNA from cells at different time points. We subsequently used microRNA microarray to screen for promising microRNA candidates, and uncovered two microRNAs that exhibited significant changes during the course of cellular calcification. This trend was accompanied by similar changes in culture media for one of the candidate microRNAs described above. We further tested the expression level of this microRNA (miR-125b) in the ex vivo and in vivo model, and found that miR-125b decreased successively over time during the calcification process in aortas and sera as well. These findings, in combination, suggest that miR-125b can be a promising biomarker for predicting the progression of uremia-associated vascular calcification. Finally, we examined whether the circulating miR-125b levels among patients with end-stage renal disease were associated with the presence of vascular calcification. From 88 patients, we discovered that high serum miR-125b levels were significantly associated with the presence of aortic arch calcification, independent of age and mineral-bone disorder parameters. Furthermore, baseline serum miR-125b levels were predictive of worsening vascular calcification severity among survivors 2 years later, indicating that miR-125b can be a promising biomarker for predicting uremic vascular calcification progression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T02:13:56Z (GMT). No. of bitstreams: 1 ntu-106-D02447004-1.pdf: 19223996 bytes, checksum: 84d042222508afd976e1bb81e94f5b22 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書………………………………………………………. I 誌謝………………………………………………………………………. II 中文摘要…………………………………………………………………. III 英文摘要………………………………………………………………..... V 縮寫表…………………………………………………………………… VII 目錄……………………………………………………………………… 1 Introduction………………………………………………………………. 4 Materials and Methods…………………………………………………… 12 1. Cell culture and its condition …………………………………… 12 2. Induction of cellular calcification ………………………………. 12 3. Phenotype characterization ……………………………………. 12 4. Pre-Test …………………………………………………………. 13 5. Extraction of cellular/medial RNA, and quantitative reverse transcription (RT) and polymerase chain reaction (PCR)……….. 13 6. MicroRNA microarray ………………………………………….. 16 7. Apoptotic assay ………………………………………………..... 16 8. Manipulating miRNA levels in vitro ………………………….... 16 9. Establishment of the in vivo model…………………………….. 17 10. Establishment of the ex vivo model …………………………… 18 11. Western blot analysis ………………………………………….. 18 12. Recruitment of patients with vascular calcification tendency…. 19 13. Quantitation of circulating miRNA ……………………………. 19 14. Semi-quantitation of clinical vascular calcification …………… 21 15. Statistical approaches to clinical data ………………………….. 21 Results ..................................................................................... 23 1. In vitro rat and human bio-mineralization model………………. 23 2. MiRNA microarray screening for potential candidates ………… 23 3. Detecting candidate miRNAs in culture media and model cells ... 24 4. Evaluating miR-125b expression levels in the ex vivo model ….. 25 5. Evaluating miR-125b expression levels in the in vivo model …... 25 6. Evaluating the functional role of miR-125b in calcification ……. 26 7. Assessing the relationship between serum miR-125b and clinical vascular calcification ……………………………………………. 26 8. Baseline serum miR-125b levels predicted the risk of calcification progression at follow-up ……………………………………….... 28 9. Validation in an independent patient cohort …………………..... 30 Discussion ……………………………………………………………….. 32 Conclusion ……………………………………………………………….. 36 Future works ……………………………………………………………... 37 Tables ……………………………………………………………………. 39 Figures and figure legends ………………………………………………. 46 References ……………………………………………………………….. 96 Appendix ……………………………………………………………….. 108 | |
dc.language.iso | en | |
dc.title | 微小核糖核酸125b預測尿毒症相關血管鈣化存在及惡化危險性 | zh_TW |
dc.title | Circulating MicroRNA-125b Predicts the Presence and Progression of Uremic Vascular Calcification | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 姜至剛(Chih-Kang Chiang),鄭劍廷,林石化(Shih-Hua Lin),楊智偉 | |
dc.subject.keyword | 生物指標,慢性腎臟病,末期腎病,微小核糖核酸,高磷血症,尿毒症,血管鈣化, | zh_TW |
dc.subject.keyword | biomarker,chronic kidney disease,end-stage renal disease,microRNA,hyperphosphatemia,uremia,vascular calcification, | en |
dc.relation.page | 115 | |
dc.identifier.doi | 10.6342/NTU201704395 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-11-22 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 毒理學研究所 | zh_TW |
顯示於系所單位: | 毒理學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 18.77 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。